માથા અને ગરદનનું કેન્સર
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
ક્યાં જવું
આ ટ્રાયલ માટે ભારતમાં 6 હોસ્પિટલો દર્દીઓ લઈ રહી છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
સ્પોન્સર: Janssen Research & Development, LLC
ClinicalTrials.gov પર NCT07276399
રજિસ્ટ્રી પર છેલ્લે 25 Sep 2026 ના રોજ અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું